Abstract
Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
Keywords: Heregulin, HER3 receptor, tumorigenicity, breast cancer.
Current Pharmaceutical Design
Title:Heregulin in Breast Cancer: Old Story, New Paradigm
Volume: 20 Issue: 30
Author(s): Ashwani Khurana, Anatilde Gonzalez-Guerrico and Ruth Lupu
Affiliation:
Keywords: Heregulin, HER3 receptor, tumorigenicity, breast cancer.
Abstract: Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
Export Options
About this article
Cite this article as:
Khurana Ashwani, Gonzalez-Guerrico Anatilde and Lupu Ruth, Heregulin in Breast Cancer: Old Story, New Paradigm, Current Pharmaceutical Design 2014; 20 (30) . https://dx.doi.org/10.2174/1381612819666131125151519
DOI https://dx.doi.org/10.2174/1381612819666131125151519 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) Effects of a Series of Acidic Drugs on L-Lactic Acid Transport by the Monocarboxylate Transporters MCT1 and MCT4
Current Pharmaceutical Biotechnology Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Current Clinical Pharmacology The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Cellular Receptors of Extracellular Matrix Molecules
Current Pharmaceutical Design Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells
Current Cancer Drug Targets New Alkyl-Lipid Blockers of SK3 Channels Reduce Cancer Cell Migration and Occurrence of Metastasis
Current Cancer Drug Targets NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) 10 Years of SELDI: What Have we Learnt?
Current Proteomics Novel Resveratrol-chalcone Derivatives: Synthesis and Biological Evaluation
Mini-Reviews in Medicinal Chemistry Gut Alterations in Septic Patients: A Biochemical Literature Review
Reviews on Recent Clinical Trials The Toxicogenetics of Antirretroviral Therapy: The Evil Inside
Current Medicinal Chemistry Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
Current Cancer Drug Targets Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets The Application of Natural Products in Cancer Therapy by Targeting Apoptosis Pathways
Current Drug Metabolism Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued) DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy
Current Pharmacogenomics and Personalized Medicine Patent Selections
Recent Patents on Biotechnology Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
Current Cancer Drug Targets On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy